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(EQ-5D), disease severity (DLQI), resource utilisation and productivity losses was 
collected from patient questionnaires. Patient characteristics and type of treatment 
were collected from patient records. Prescribed medications were collected from 
national drug registry data. RESULTS: During 12 months, 64% of the patients used 
only emollients and topical corticosteroids and 21% used systemic treatment (not 
biological). During part of or during the whole period 15% used biological treatment. 
Mean direct cost per patient related to in and out-patient care was estimated to a488, 
and indirect cost was a758. Cost for drugs was a1892 per patient and cost for light 
treatment was a930. QoL according to EQ-5D was 0.73 (SD 0.25), VAS 72.7 (SD 
20.6) and DLQI was 7.0 (SD 6.6) corresponding to “moderate effect on patient’s life”. 
CONCLUSIONS: Patients with more extensive psoriasis problems experienced lower 
QoL according to EQ-5D and higher discomfort and a larger effect on their lives 
according to DLQI. Direct and indirect costs increased with disease severity. Costs 
increased with the use of more potent drugs (biological and systemic drugs).
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OBJECTIVES: To describe costs of glaucoma treatment in Denmark by treatment 
sequence. METHODS: The analyses were based on registry data. A new or incident 
patient was deﬁned as a patient who did not use any medicine related to glaucoma 
for 6 months—that is, the study estimated the number of new patients in a 5.5 year 
period (from mid-2002 to 2007). New (incident) glaucoma patients (primary open-
angle glaucoma or ocular hypertension) were deﬁned via their “ﬁrst” use of prescribed 
medicine related to glaucoma (that is, via the ATC-codes) and the patients were identi-
ﬁed in the Danish Register of Medicinal Product Statistics for the years 2002–2007. 
Subsequently a cross sectional analysis for 2007 was performed including use of 
medicine related to glaucoma and use of services in the primary (ophthalmologists’ 
services) and secondary care services (relevant out-patient treatment and admissions 
—relevance deﬁned by a ICD10 code). Patients were categorized according to their 
number of treatment changes. RESULTS: Based on these data the yearly Danish inci-
dence was estimated to 1.2 per 1000 persons. The sex ratio (male/female) was 
44%/56% with a mean age of 68 and 71 years, respectively. Thirty-seven percent of 
the patients were in their ﬁrst treatment sequence (that is, no treatment changes), 21 
% were in their second, and 43 % of the patients had 3 or more treatment sequences. 
The number of treatment sequences inﬂuenced cost. The total costs of glaucoma 
(public payer perspective) were DKK 2200 (a300) per year for a patient in ﬁrst treat-
ment sequence whereas the corresponding costs for a patient with 3 or more treatment 
sequences were DKK 4600 (a610). Drug cost accounted for 62% of the total. CON-
CLUSIONS: Drugs represent the bulk of the costs of glaucoma and the costs increases 
with the number of treatment changes.
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OBJECTIVES: Use decision making tools to determine which of three alternatives—
Cochlear Implants, Hearing aids or no treatment- assure that a person, who suffers 
from Deep Neursosensorial Hypoacusia, will achieve the best cost-productivity rela-
tion for his or her life. METHODS: This study is based on a decision making analysis 
methodology which includes a description of the problem, a bibliographic review, a 
formulation of the problem, data analysis and incorporation, a mathematical model 
and results analysis. The problem is described as an alternatives issue concerning dif-
ferent treatments for Deep Neurosensorial Hypoacusia and a cost-productivity rela-
tion in order to evaluate each of the alternatives. This relation is measured as the NPV 
of the salary cash ﬂow that the patient expects to receive during his/her productive 
life as compared with the treatment and education costs. Actual data from the 
Cochlear Group of the Fundacion Santafe concerning audiology and language com-
prehension levels from patients using different treatments for deep deafness is analyzed 
in order to generate probability distributions and develop an inﬂuence diagram. 
Finally, a sensitivity analysis is conducted in order to verify the robustness of the 
solution obtained. RESULTS: As a result of the study was obtained that the cochlear 
implant provides a cost-productivity relation of COP$253,936,210 (US$123,871), 
Hearing aids: COP$ 138,307,940 (US$67,467) and not following any treatment: 
COP$107,510,318 (US$52,444). According to this assessment, the cochlear implant 
is the best treatment. CONCLUSIONS: According to the results, individuals who use 
a cochlear implant have a productivity of 1.5 times higher for individuals with hearing 
aids and almost 3 times higher than individuals who do not follow any treatment. 
This conﬁrms the excellent performance in terms of effectiveness and utility of the 
cochlear implant compared to hearing aids. The sensitivity analysis conducted showed 
that the cochlear implant is the best decision in a real scenario.
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OBJECTIVES: Non-compliance is frequently reported as a cause of treatment failure 
of oral antimicrobials. As the long-term injectable cefovecin eliminates non-compliance, 
the study objective was to investigate the impact of non-compliance on the costs and 
effectiveness of treatment of superﬁcial pyoderma, wounds and abscesses (SP-W-A), 
and deep pyoderma (DP) in dogs in Germany. METHODS: A Markov model, contain-
ing the health states “Worsening”, “Status quo”, “Improvement”, “Cure”, and 
“Relapse”, was adapted to Germany to calculate costs and beneﬁts (days without 
symptoms of SP-W-A or DP) over a 6-months (SP-WA) and 1-year (DP) period, for 
dogs on cefovecin versus amoxicillin/clavulanic acid (amoxi/clav). Efﬁcacy parameters 
were derived from clinical studies. For amoxi/clav, ﬁrst line treatment failure caused 
by non-compliance was estimated at 13.6% of all dogs, calculated from published 
literature. Cost data were derived from German ofﬁcial price and tariff lists (2009, 
dog owner’s perspective). All relevant input parameters were varied extensively in 
one-way and probabilistic sensitivity analyses. RESULTS: Cefovecin was more effec-
tive than amoxi/clav, with 161 versus 156 days without symptoms of SP-W-A and 
316 versus 307 days without symptoms of DP. Up to a bodyweight (b.w.) of 15 kg 
(SP-W-A) or 16 kg (DP), cefovecin was a dominant strategy, i.e. also cost-saving when 
considering total therapy expenditure (including anamnesis, diagnosis, treatment). In 
dogs of 25 kg b.w., total therapy costs for cefovecin were slightly increased versus 
comparator, a297.25 versus a272.72 (SP-W-A) and a 498.60 versus a477.75 (DP). 
Model outcomes were sensitive to changes of non-compliance data, but remained 
robust when varying other parameters. CONCLUSIONS: Considering non-compli-
ance with oral treatments as a cause of treatment failure, higher drug and administra-
tion costs of cefovecin became totally or partly offset by the increased incremental 
efﬁcacy resulting in less costs for supplementary treatments of relapses and failures.
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OBJECTIVES: Topical prostaglandin analogs combined with timolol demonstrate 
strong intra-ocular pressure lowering effect and are indicated in second line treatment. 
This study aims to estimate the 5-years cost effectiveness of Duotrav® and Xalacom® 
in second line glaucoma treatment in France from the perspective of the health care 
system. METHODS: A 5 year Markov model was built to populate the treatment of 
two cohorts of glaucoma patients. Time to treatment modiﬁcation, a key cost factor 
in real life, was estimated on the basis of an analysis of the UK GPRD database and 
a hazard-ratio (DuoTrav vs Xalacom) taken from a French observational study. Visual 
ﬁeld defect (VFD) occurrence rathes by treatment line were estimated from the litera-
ture. French standard costs were applied. Sensitivity analyses were carried out. 
RESULTS: Average times to treatment changes were 38.0 and 31.1 months for 
Duotrav and Xalacom, respectively. A total of 45.4% of the patients remained with 
their treatment at 5 years in the Duotrav cohort compared with 29.1% in the Xalacom 
group. The clinical beneﬁt of Duotrav was 0.06 less new VFDs on average per patient. 
The longer duration of treatment with Duotrav was associated with an extra costs of 
a144, an amount that was totally offset by a decrease in operating procedures (a98.7) 
and cost of rescue medications (a98.5). Other resources used (visits, exams..) were 
similar. Total costs were lower in the Duotrav cohort (a81.8) than in the Xalacom 
cohort. Sensitivity analyses conﬁrmed these ﬁndings. CONCLUSIONS: Treatment 
persistency is a key indicator of the effectiveness of chronic disease treatment in daily 
practice. The longer duration of treatment with Duotrav as compared with Xalacom 
lead to better glaucoma control, less VFD progression, and lower medical care costs. 
According to this analysis, DuoTrav economically dominates Xalacom.
PSS19
CEFOVECIN AS TREATMENT OF SUPERFICIAL PYODERMA, WOUNDS 
AND ABSCESSES IN DOGS: ESTIMATION OF THE HEALTH AND 
ECONOMIC IMPACT OF ELIMINATING ORAL MEDICATION NON-
COMPLIANCE IN THE UNITED STATES
Van Vlaenderen I1, Poulsen Nautrup B2, Gasper SM3
1Deloitte, Diegem, Belgium, 2EAH Consulting, Juelich, Germany, 3Pﬁzer Animal Health, Inc., 
New York, NY, USA
OBJECTIVES: Cefovecin, an injectable antimicrobial, maintains a therapeutic tissue 
concentration for approximately 14 days, and hence eliminates non-compliance 
reported with oral comparators. This study compared treatment costs and effectiveness 
of oral medication to cefovecin in resolving superﬁcial pyoderma, wounds, and 
abscesses (SP-W-A) in dogs. METHODS: A Markov model was developed to reﬂect 
treatment with cefovecin versus oral amoxicillin/clavulanic acid (amoxi/clav) over a 
six months period. The health states “Worsening”, “Status quo”, “Improvement”, 
“Cure”, and “Relapse” were included to reﬂect treatment costs and outcomes of ﬁrst, 
second and third line therapy protocols and account for treatment relapses. Effective-
ness parameters were derived from published clinical studies. For amoxi/clav, ﬁrst 
line treatment failure caused by non-compliance was estimated at 13.6% of all dogs 
